Overview of ZPL-3893787 (ZPL-389) clinical trial for atopic dermatitis - European Medical Journal

Overview of ZPL-3893787 (ZPL-389) clinical trial for atopic dermatitis

Dermatology

Thomas Werfel, MD, from Hannover Medical School, Hannover, Germany, gives an overview of a phase 2a proof-of-concept clinical trial evaluating ZPL-3893787 (ZPL-389) for the treatment of moderate-to-severe atopic dermatitis in adults. The trial outcomes to date are presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016, held from 11-15 June in Austria, Vienna.

This content is supported by Ziarco Pharma Ltd.

EAACI is an independent organisation and cannot, therefore, endorse medicines or products.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now